Nordic Nanovector ASA – Results for Second Quarter and First Half Year 2017
All operations on track, strong data presented at ICML confirm Betalutin®’s promising efficacy and safety profile in recurrent iNHL patients, pivotal Phase 2 study, PARADIGME to start in 2H 2017Oslo, Norway, 23 August 2017 Nordic Nanovector ASA (OSE: NANO) announces results for the second quarter and half year of 2017. A presentation by the company’s senior management team will take place today at 8:30 a.m. CEST in Oslo - details below. Nordic Nanovector reported continued solid operational progress during the second quarter, with very encouraging clinical results from the ongoing